<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2019-12-20" updated="2019-12-21">
  <drugbank-id primary="true">DB15594</drugbank-id>
  <name>Brilliant blue G</name>
  <description>Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.[A188841,A188844] This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy. Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]</description>
  <cas-number>6104-58-1</cas-number>
  <unii>M1ZRX790SI</unii>
  <average-mass>854.02</average-mass>
  <monoisotopic-mass>853.28313753</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A188841</ref-id>
        <pubmed-id>14660466</pubmed-id>
        <citation>Gandorfer A, Haritoglou C, Kampik A: Staining of the ILM in macular surgery. Br J Ophthalmol. 2003 Dec;87(12):1530; author reply 1530. doi: 10.1136/bjo.87.12.1530.</citation>
      </article>
      <article>
        <ref-id>A188844</ref-id>
        <pubmed-id>26425352</pubmed-id>
        <citation>Semeraro F, Morescalchi F, Duse S, Gambicorti E, Russo A, Costagliola C: Current Trends about Inner Limiting Membrane Peeling in Surgery for Epiretinal Membranes. J Ophthalmol. 2015;2015:671905. doi: 10.1155/2015/671905. Epub 2015 Sep 3.</citation>
      </article>
      <article>
        <ref-id>A188847</ref-id>
        <pubmed-id>16829804</pubmed-id>
        <citation>Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T: Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina. 2006 Jul-Aug;26(6):631-6. doi: 10.1097/01.iae.0000236469.71443.aa.</citation>
      </article>
      <article>
        <ref-id>A188853</ref-id>
        <pubmed-id>31004281</pubmed-id>
        <citation>Guber J, Pereni I, Scholl HPN, Guber I, Haynes RJ: Outcomes after Epiretinal Membrane Surgery with or Without Internal Limiting Membrane Peeling. Ophthalmol Ther. 2019 Jun;8(2):297-303. doi: 10.1007/s40123-019-0185-7. Epub 2019 Apr 19.</citation>
      </article>
      <article>
        <ref-id>A188871</ref-id>
        <pubmed-id>12799245</pubmed-id>
        <citation>Sheard RM, Sethi C, Gregor Z: Acute macular pucker. Ophthalmology. 2003 Jun;110(6):1178-84. doi: 10.1016/S0161-6420(03)00266-5.</citation>
      </article>
      <article>
        <ref-id>A188874</ref-id>
        <pubmed-id>19561782</pubmed-id>
        <citation>Konidaris V, Androudi S, Brazitikos P: Myopic traction maculopathy: study with spectral domain optical coherence tomography and review of the literature. Hippokratia. 2009 Apr;13(2):110-3.</citation>
      </article>
      <article>
        <ref-id>A188880</ref-id>
        <pubmed-id>21372016</pubmed-id>
        <citation>Awad D, Schrader I, Bartok M, Mohr A, Gabel D: Comparative toxicology of trypan blue, brilliant blue G, and their combination together with polyethylene glycol on human pigment epithelial cells. Invest Ophthalmol Vis Sci. 2011 Jun 9;52(7):4085-90. doi: 10.1167/iovs.10-6336.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L10830</ref-id>
        <title>Brilliant Blue G Opthalmic solution</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209569s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10839</ref-id>
        <title>Brilliant Blue G MSDS, Cayman Chem</title>
        <url>https://www.caymanchem.com/msdss/14320m.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>This drug is indicated for selectively staining the internal limiting membrane (ILM).[L10830]</indication>
  <pharmacodynamics>Brilliant Blue G aids in ophthalmologic surgery by rendering it easier to identify the internal limiting membrane (ILM) for surgical removal.[L10830]&#13;
</pharmacodynamics>
  <mechanism-of-action>The internal limiting membrane (ILM) is a thin and translucent structure that demarcates the transition from the retina from the vitreous body of the eye. It acts as a scaffold on which excessive tissue can grow, which results in visual distortion when it is projected onto the neighbouring retina. This causes visual loss and/or distortion.[A188853] &#13;
&#13;
An epiretinal membrane (also known as ERM) is a fibrous type of tissue that can be found on the inner surface of the retina and occurs idiopathically, and in some cases, retinal detachment and inflammation. It is often found on the surface of the internal limiting membrane (ILM), causing visual loss and distortion.[A188853] The above condition as well as the associated macular pucker[A188871] or traction maculopathy[A188874] can affect the ILM, contributing to visual complications. The removal of the ILM with or without vitrectomy is often a simple solution to these conditions.&#13;
&#13;
Brilliant Blue G specifically stains the internal limiting membrane (ILM) in the eye without staining the epiretinal membrane or the retina, allowing for easier surgical removal. The mechanism of its specific staining that is limited to the ILM is currently not fully understood.[L10830]</mechanism-of-action>
  <toxicity>The intraperitoneal TDLO in rats is 100 mg/kg.[L10839] No overdose information is available at this time.[L10830] When compared to other ophthalmological dyes, brilliant blue G appears to have a comparable safety profile.[A188880] Ensure to remove the dye immediately after staining.[L10830]</toxicity>
  <metabolism/>
  <absorption>Due to the fact that this drug is administered by intravitreal injection and subsequently removed after staining, it is not expected to be significantly absorbed systemically.[L10830]</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>This dye is removed in a clinical setting after the surgical procedure in which it was used.[L10830]</route-of-elimination>
  <volume-of-distribution>This drug is administered via intravitreal injection and likely distributes only to parts of the eye.[L10830]</volume-of-distribution>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Acid Blue 90</synonym>
    <synonym language="english" coder="">C.I. Acid Blue 90</synonym>
    <synonym language="english" coder="">Coomassie Brilliant Blue G</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Aniline Compounds</category>
      <mesh-id>D000814</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Indicators and Reagents</category>
      <mesh-id>D007202</mesh-id>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB15594.pdf?1576874923</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.35</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-7.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.46e-05 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>sodium 3-({[4-({4-[(4-ethoxyphenyl)amino]phenyl}[(1E,4E)-4-{ethyl[(3-sulfonatophenyl)methyl]iminiumyl}-2-methylcyclohexa-2,5-dien-1-ylidene]methyl)-3-methylphenyl](ethyl)amino}methyl)benzene-1-sulfonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>sodium 3-({[4-({4-[(4-ethoxyphenyl)amino]phenyl}[(1E,4E)-4-{ethyl[(3-sulfonatophenyl)methyl]iminio}-2-methylcyclohexa-2,5-dien-1-ylidene]methyl)-3-methylphenyl](ethyl)amino}methyl)benzenesulfonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>854.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>853.28313753</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC(=CC=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC(=CC=C2)S([O-])(=O)=O)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C47H48N3NaO7S2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C47H49N3O7S2.Na/c1-6-49(31-35-11-9-13-43(29-35)58(51,52)53)40-21-25-45(33(4)27-40)47(37-15-17-38(18-16-37)48-39-19-23-42(24-20-39)57-8-3)46-26-22-41(28-34(46)5)50(7-2)32-36-12-10-14-44(30-36)59(54,55)56;/h9-30H,6-8,31-32H2,1-5H3,(H2,51,52,53,54,55,56);/q;+1/p-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RWVGQQGBQSJDQV-UHFFFAOYSA-M</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>141.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>258.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>91.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-2.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1mg/mL</value>
      <source>https://www.sigmaaldrich.com/catalog/product/sial/b0770?lang=en&amp;region=CA</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4884338</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009797</id>
      <name>Internal limiting membrane (ILM)</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A188880</ref-id>
            <pubmed-id>21372016</pubmed-id>
            <citation>Awad D, Schrader I, Bartok M, Mohr A, Gabel D: Comparative toxicology of trypan blue, brilliant blue G, and their combination together with polyethylene glycol on human pigment epithelial cells. Invest Ophthalmol Vis Sci. 2011 Jun 9;52(7):4085-90. doi: 10.1167/iovs.10-6336.</citation>
          </article>
          <article>
            <ref-id>A188847</ref-id>
            <pubmed-id>16829804</pubmed-id>
            <citation>Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T: Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina. 2006 Jul-Aug;26(6):631-6. doi: 10.1097/01.iae.0000236469.71443.aa.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L10830</ref-id>
            <title>Brilliant Blue G Opthalmic solution</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209569s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>